Aclaris Therapeutics (ACRS) Competitors $1.80 +0.05 (+2.86%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.82 +0.01 (+0.83%) As of 08/22/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS vs. NRIX, NAGE, PHAR, AVBP, SANA, GYRE, OCS, DNA, ATAI, and IMTXShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Nurix Therapeutics (NRIX), Niagen Bioscience (NAGE), Pharming Group (PHAR), ArriVent BioPharma (AVBP), Sana Biotechnology (SANA), Gyre Therapeutics (GYRE), Oculis (OCS), Ginkgo Bioworks (DNA), atai Life Sciences (ATAI), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. Its Competitors Nurix Therapeutics Niagen Bioscience Pharming Group ArriVent BioPharma Sana Biotechnology Gyre Therapeutics Oculis Ginkgo Bioworks atai Life Sciences Immatics Nurix Therapeutics (NASDAQ:NRIX) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership. Do analysts prefer NRIX or ACRS? Nurix Therapeutics presently has a consensus target price of $28.87, indicating a potential upside of 184.68%. Aclaris Therapeutics has a consensus target price of $8.71, indicating a potential upside of 384.13%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Nurix Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.81Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Is NRIX or ACRS more profitable? Nurix Therapeutics has a net margin of -234.57% compared to Aclaris Therapeutics' net margin of -802.03%. Aclaris Therapeutics' return on equity of -34.01% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nurix Therapeutics-234.57% -45.26% -34.71% Aclaris Therapeutics -802.03%-34.01%-24.18% Which has more volatility & risk, NRIX or ACRS? Nurix Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Which has higher valuation & earnings, NRIX or ACRS? Aclaris Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNurix Therapeutics$54.55M14.21-$193.57M-$2.61-3.89Aclaris Therapeutics$18.72M10.42-$132.07M-$1.37-1.31 Does the media refer more to NRIX or ACRS? In the previous week, Nurix Therapeutics had 3 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 4 mentions for Nurix Therapeutics and 1 mentions for Aclaris Therapeutics. Nurix Therapeutics' average media sentiment score of 1.14 beat Aclaris Therapeutics' score of 1.11 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in NRIX or ACRS? 98.3% of Aclaris Therapeutics shares are held by institutional investors. 7.4% of Nurix Therapeutics shares are held by insiders. Comparatively, 5.6% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryAclaris Therapeutics beats Nurix Therapeutics on 9 of the 17 factors compared between the two stocks. Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$195M$2.53B$5.81B$9.76BDividend YieldN/A1.67%4.39%4.06%P/E Ratio-1.3122.9031.3626.05Price / Sales10.42516.56387.8788.42Price / CashN/A179.1038.0259.36Price / Book1.485.939.536.60Net Income-$132.07M$31.83M$3.26B$265.65M7 Day Performance-3.74%1.89%2.14%2.00%1 Month Performance7.14%1.62%3.22%0.46%1 Year Performance48.76%9.25%30.18%18.88% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics2.7828 of 5 stars$1.80+2.9%$8.71+384.1%+48.8%$195M$18.72M-1.31100Positive NewsNRIXNurix Therapeutics2.6336 of 5 stars$10.20-3.6%$28.87+183.0%-57.8%$808.83M$54.55M-3.91300News CoveragePositive NewsHigh Trading VolumeNAGENiagen Bioscience1.1478 of 5 stars$10.12+1.0%$13.42+32.6%+184.3%$799.12M$99.60M48.19120Analyst DowngradePHARPharming Group2.3672 of 5 stars$12.39+6.4%$30.00+142.1%+80.3%$798.20M$297.20M-95.31280Gap UpAVBPArriVent BioPharma2.3115 of 5 stars$19.24-1.5%$39.14+103.4%-17.1%$792.31MN/A-4.7940Positive NewsSANASana Biotechnology2.9545 of 5 stars$3.40+2.1%$8.00+135.3%-38.7%$791.90MN/A-3.21380GYREGyre Therapeutics0.0269 of 5 stars$7.85-3.6%N/A-36.3%$783.99M$105.76M785.7940Gap UpOCSOculis2.9945 of 5 stars$18.06+0.9%$35.33+95.6%+49.6%$781.56M$780K-6.842News CoverageEarnings ReportAnalyst ForecastDNAGinkgo Bioworks1.0612 of 5 stars$13.79+4.6%$8.50-38.4%+53.6%$780.25M$227.04M-2.35640ATAIatai Life Sciences3.5953 of 5 stars$4.05+4.4%$11.25+177.8%+248.9%$777.31M$310K-5.8780Analyst DowngradeAnalyst RevisionIMTXImmatics1.897 of 5 stars$6.21-1.9%$14.67+136.2%-49.2%$769.41M$168.65M-9.55260News CoverageHigh Trading Volume Related Companies and Tools Related Companies Nurix Therapeutics Competitors Niagen Bioscience Competitors Pharming Group Competitors ArriVent BioPharma Competitors Sana Biotechnology Competitors Gyre Therapeutics Competitors Oculis Competitors Ginkgo Bioworks Competitors atai Life Sciences Competitors Immatics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRS) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access